Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
PROCTER & GAMBLE HEALTH ACTAVIS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PROCTER & GAMBLE HEALTH Jun-23 |
ACTAVIS Dec-18 |
PROCTER & GAMBLE HEALTH/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 5,366 | 16,117 | - | |
Low | Rs | 3,883 | 10,811 | - | |
Sales per share (Unadj.) | Rs | 740.7 | 3,953.4 | - | |
Earnings per share (Unadj.) | Rs | 138.2 | -1,273.4 | - | |
Cash flow per share (Unadj.) | Rs | 155.2 | 416.6 | - | |
Dividends per share (Unadj.) | Rs | 95.00 | 0 | - | |
Avg Dividend yield | % | 2.1 | 0 | - | |
Book value per share (Unadj.) | Rs | 447.6 | 16,305.9 | - | |
Shares outstanding (eoy) | m | 16.60 | 332.60 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 6.2 | 3.4 | 183.3% | |
Avg P/E ratio | x | 33.5 | -10.6 | -316.4% | |
P/CF ratio (eoy) | x | 29.8 | 32.3 | 92.2% | |
Price / Book Value ratio | x | 10.3 | 0.8 | 1,251.1% | |
Dividend payout | % | 68.7 | 0 | - | |
Avg Mkt Cap | Rs m | 76,761 | 4,478,069 | 1.7% | |
No. of employees | `000 | NA | 16.9 | 0.0% | |
Total wages/salary | Rs m | 2,062 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 77,804.7 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | -25,060.9 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 12,296 | 1,314,899 | 0.9% | |
Other income | Rs m | 184 | 25,145 | 0.7% | |
Total revenues | Rs m | 12,480 | 1,340,044 | 0.9% | |
Gross profit | Rs m | 3,247 | 34,457 | 9.4% | |
Depreciation | Rs m | 281 | 562,091 | 0.0% | |
Interest | Rs m | 8 | 75,877 | 0.0% | |
Profit before tax | Rs m | 3,142 | -578,366 | -0.5% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 147,507 | 0.0% | |
Tax | Rs m | 847 | -7,330 | -11.6% | |
Profit after tax | Rs m | 2,295 | -423,530 | -0.5% | |
Gross profit margin | % | 26.4 | 2.6 | 1,007.6% | |
Effective tax rate | % | 27.0 | 1.3 | 2,127.9% | |
Net profit margin | % | 18.7 | -32.2 | -57.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,713 | 539,303 | 2.2% | |
Current liabilities | Rs m | 6,791 | 477,085 | 1.4% | |
Net working cap to sales | % | 40.0 | 4.7 | 846.0% | |
Current ratio | x | 1.7 | 1.1 | 152.6% | |
Inventory Days | Days | 263 | 20 | 1,341.8% | |
Debtors Days | Days | 343 | 66 | 518.0% | |
Net fixed assets | Rs m | 10,617 | 148,839 | 7.1% | |
Share capital | Rs m | 166 | 0 | - | |
Net worth | Rs m | 7,431 | 5,423,345 | 0.1% | |
Long term debt | Rs m | 0 | 1,909,756 | 0.0% | |
Total assets | Rs m | 22,330 | 8,477,923 | 0.3% | |
Interest coverage | x | 409.1 | -6.6 | -6,176.8% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.2 | 355.0% | |
Return on assets | % | 10.3 | -4.1 | -251.4% | |
Return on equity | % | 30.9 | -7.8 | -395.4% | |
Return on capital | % | 42.4 | -4.8 | -875.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,360 | 469,764 | 0.5% | |
From Investments | Rs m | -215 | 258,074 | -0.1% | |
From Financial Activity | Rs m | -985 | -806,256 | 0.1% | |
Net Cashflow | Rs m | 1,160 | -78,026 | -1.5% |
Compare PROCTER & GAMBLE HEALTH With: ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Compare PROCTER & GAMBLE HEALTH With: LAURUS LABS FREDUN PHARMA BH.IMMUN&BIO IND. SWIFT ORCHID PHARMA
After opening the day on high, Indian share markets continued the momentum as the session progressed and ended the higher.